Vaso-Occlusive Crisis in Sickle Cell Disease: Emerging Therapies, Clinical Trials, and Pipeline Innovations Shaping the Future of Treatment - 2025 | DelveInsight

DelveInsight's "Vaso-Occlusive Crisis (VOC) Associated With Sickle Cell Disease - Pipeline Insight, 2025" provides an in-depth analysis of emerging therapies targeting vaso-occlusive crisis (VOC), a severe and recurring complication of sickle cell disease. Despite current standards of care, including hydroxyurea, patients continue to experience frequent vaso occlusive sickle cell crisis, underscoring the urgent need for effective interventions in sickle cell anemia vaso occlusive crisis treatment.

The VOC pipeline is diversifying with therapies across multiple mechanisms, including P-selectin inhibitors (Inclacumab, Pfizer; Crizanlizumab, Novartis), hemoglobin-modulating agents, pyruvate kinase activators (Etavopivat, Global Blood Therapeutics), and gene-editing approaches (Exagamglogene autotemcel/Exa-cel, Vertex Pharmaceuticals). These candidates aim to reduce the frequency and severity of vaso occlusive crisis in sickle cell disease, addressing both the underlying hemolysis and inflammation that drive crises.

Clinical trials also include small molecules, biologics, and cell-based therapies, reflecting a shift toward precision medicine strategies tailored to individual patient profiles. As these therapies advance, the vaso occlusive crisis treatment landscape is expected to transform, moving beyond symptomatic relief toward disease-modifying interventions that improve long-term outcomes and quality of life for patients with sickle cell disease.

Interested in learning more about the current treatment landscape and the key drivers shaping the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline? Click here: https://www.delveinsight.com/sample-request/vaso-occlusive-crisis-associated-with-sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Report
• DelveInsight's Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment.
• The leading Vaso-Occlusive Crisis Associated With Sickle Cell Disease companies include Global Blood Therapeutics, Asklepion Pharmaceuticals, LLC, Prolong Pharmaceuticals, CSL Behring, GlycoMimetics, Hillhurst Pharmaceuticals, and others are evaluating their lead assets to improve the Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment landscape.
• Key Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline therapies in various stages of development include Inclacumab, L-citrulline, SANGUINATE, CSL889, GMI-1687, HBI 002, and others.
• In August 2025, Pfizer announced that its Phase III THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, did not meet its primary endpoint of significantly reducing the rate of vaso-occlusive crises in patients with SCD. The study involved participants aged 16 years and older and administered inclacumab every 12 weeks over 48 weeks. Despite the lack of efficacy, inclacumab was generally well tolerated in the trial.
• In December 2024, the HIBISCUS Phase 2 trial results were presented, demonstrating that etavopivat significantly reduced the incidence of vaso-occlusive crises in patients with SCD over a 52-week period. The trial highlighted etavopivat's potential as a novel oral therapy for managing VOCs in SCD patients.
• In April 2024, a study published in the New England Journal of Medicine reported that exagamglogene autotemcel (exa-cel), a gene therapy for severe SCD, eliminated vaso-occlusive crises in 97% of patients for a period of 12 months or more. This one-time treatment involves editing the patient's own stem cells to produce high levels of fetal hemoglobin, offering a potential functional cure for SCD.

Request a sample and discover the recent breakthroughs happening in the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape at https://www.delveinsight.com/sample-request/vaso-occlusive-crisis-associated-with-sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Overview
Vaso-occlusive crisis (VOC) is a common and painful complication of sickle cell disease (SCD), characterized by the blockage of blood flow due to the abnormal sickling of red blood cells. This blockage causes ischemia and intense pain, often requiring urgent medical attention. Also referred to as vaso occlusive sickle cell crisis, these episodes can vary in frequency and severity and significantly impact the quality of life for individuals with sickle cell anemia. The underlying mechanism involves sickled red blood cells adhering to the blood vessel walls, leading to inflammation and obstruction, which triggers the vaso occlusive crisis in sickle cell disease.

Effective sickle cell anemia vaso occlusive crisis treatment aims to alleviate pain, reduce inflammation, and prevent further sickling events. Management typically includes hydration, pain control with analgesics, and sometimes blood transfusions. Advances in therapy have introduced targeted treatments that address the root causes of vaso occlusive crisis, improving outcomes for patients. Understanding and managing vaso occlusive crisis is crucial in reducing complications and hospitalizations associated with sickle cell disease.

Find out more about Vaso-Occlusive Crisis Associated With Sickle Cell Disease medication at https://www.delveinsight.com/sample-request/vaso-occlusive-crisis-associated-with-sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Treatment Analysis: Drug Profile
Inclacumab: Global Blood Therapeutics
Global Blood Therapeutics (GBT) is developing inclacumab, a novel fully human monoclonal antibody that acts as a P-selectin inhibitor, specifically targeting patients with sickle cell disease (SCD) who experience frequent vaso-occlusive crises (VOCs). Inhibiting P-selectin has been clinically proven to reduce the occurrence of VOCs, a major complication of SCD. GBT holds an exclusive global licensing agreement with Roche for inclacumab, which has demonstrated established pharmacokinetic profiles, safety, and tolerability in over 500 patients. Currently, two pivotal Phase 3 clinical trials, known as the THRIVE (Therapy for Reduction with Inclacumab of VOC Episodes) studies, are underway to assess inclacumab's effectiveness in lowering the frequency of VOCs and hospital readmissions in SCD patients.

L-citrulline: Asklepion Pharmaceuticals
Asklepion Pharmaceuticals is developing intravenous L-citrulline, a non-essential amino acid, under a license from Vanderbilt University. Research conducted at Vanderbilt revealed that cardiopulmonary bypass significantly reduces blood citrulline levels, impairing the body's ability to produce nitric oxide-a key blood vessel dilator-during surgery and the postoperative period. L-citrulline is currently in Phase I/II clinical trials aimed at treating acute vaso-occlusive crises (VOC).

Learn more about the novel and emerging Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline therapies at https://www.delveinsight.com/sample-request/vaso-occlusive-crisis-associated-with-sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Report
• Coverage: Global
• Key Vaso-Occlusive Crisis Associated With Sickle Cell Disease Companies: Global Blood Therapeutics, Asklepion Pharmaceuticals, LLC, Prolong Pharmaceuticals, CSL Behring, GlycoMimetics, Hillhurst Pharmaceuticals, and others.
• Key Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Therapies: Inclacumab, L-citrulline, SANGUINATE, CSL889, GMI-1687, HBI 002, and others.

To dive deep into rich insights for drugs used for Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment, visit: https://www.delveinsight.com/sample-request/vaso-occlusive-crisis-associated-with-sickle-cell-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Therapeutics
6. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline: Late-Stage Products (Phase III)
7. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline: Mid-Stage Products (Phase II)
8. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.